Borate, Uma http://orcid.org/0000-0002-4958-4962
Seiter, Karen http://orcid.org/0000-0003-3838-7901
Potluri, Ravi http://orcid.org/0000-0002-0509-2659
Mazumder, Debasish
Chevli, Manoj
Prebet, Thomas http://orcid.org/0000-0002-6872-625X
Gaugler, Lona
Strocchia, Maria
Vasconcelos, Alberto
Sieluk, Jan http://orcid.org/0000-0002-1833-0273
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 16 April 2024
Accepted: 8 July 2024
First Online: 6 September 2024
Declarations
:
: Uma Borate has received grants/research support from and served as an advisory board member for AbbVie; has served as an advisory board member for Agios, Astellas, Blueprint Medicines, Genentech, Kura Oncology, Novartis, Servier, and Takeda; has received grants/research support from Incyte, Jazz Pharmaceuticals, and Pfizer; and has received honoraria from the RUNX1 Foundation. Karen Seiter has received research funding and consulting fees from Bristol Myers Squibb. Ravi Potluri and Debasish Mazumder declare employment with SmartAnalyst/Putnam Associates. Manoj Chevli, Thomas Prebet, Lona Gaugler, Maria Strocchia, and Jan Sieluk declare employment and stock ownership in Bristol Myers Squibb. Alberto Vasconcelos has received research funding support for travel/meeting attendance and declares employment and stock ownership in Bristol Myers Squibb.
: This article is based on a study of data derived from the IQVIA PharMetrics<sup>®</sup> Plus claims database. The database is de-identified and compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This article does not relate to any studies with human participants or animals performed by any of the authors.